ANTIANGIOGENIC THERAPY WITH INTRAVITREAL BEVACIZUMAB FOR RETINOPATHY OF PREMATURITY
|
|
- Anne Wilkinson
- 5 years ago
- Views:
Transcription
1 ANTIANGIOGENIC THERAPY WITH INTRAVITREAL BEVACIZUMAB FOR RETINOPATHY OF PREMATURITY HUGO QUIROZ-MERCADO, MD,* MARIA A. MARTINEZ-CASTELLANOS, MD,* MYRIAM L. HERNANDEZ-ROJAS, MD,* NELIDA SALAZAR-TERAN, MD,* ROBINSON VERNON PAUL CHAN, MD Purpose: To evaluate the role of antiangiogenic therapy with intravitreal bevacizumab for retinopathy of prematurity (ROP). Methods: In this noncomparative, prospective, interventional case series, bevacizumab was injected into the vitreous of patients with ROP in three different groups: group I, patients with stage IVa or IVb ROP who had no response to conventional treatment; group II, patients with threshold ROP who were difficult to treat with conventional therapy because of poor visualization of the retina; and group III, patients with high-risk prethreshold or threshold ROP. Results: Thirteen patients (18 eyes; mean age SD, 4 3 months; mean follow-up, 6 months) were included in the study. We found neovascular regression in 17 eyes. One patient with stage IVa ROP had spontaneous retinal reattachment after an intravitreal injection of bevacizumab. There were no serious ocular or systemic adverse events. Conclusion: The use of bevacizumab may be promising in the treatment of patients with ROP. Further studies need to be performed to determine the safety and long-term efficacy of intravitreal injection of bevacizumab, either as first-line therapy or after failure of conventional therapy. RETINA 28:S19 S25, 2008 From the *Retina Service, Asociacion Para Evitar La Ceguera en México (APEC), Mexico City, Mexico; and the Retina Service, New York Presbyterian Hospital, Weill Medical College of Cornell University, New York, New York, USA. Partially presented at the Cannes Retina Festival (American Society of Retinal Specialists [ASRS] and EuropeanVitreoretinal Society [EVRS]); Cannes, France; September 13, Presented at the Association of Paediatric Retinal Surgeons (APRS) Meeting; ST. Thomas, Virgin Islands; January 18 21, Partially published in Seminars in Ophthalmology (2007;22: ). The authors have no proprietary interest in this study. Reprints requests: Hugo Quiroz-Mercado, MD, Retina Service, Asociacion para Evitar la Ceguera en México, Vicente Garcia Torres No. 46 San Lucas Coyoacan, Mexico City, Mexico 04030; retinamex@yahoo.com Retinopathy of prematurity (ROP) is a proliferative disorder of the developing retina that continues to be a major cause of blindness in children. 1 4 In the United States, ROP is the second most common cause of blindness in children younger than 6 years of age, and it is estimated that of the 100,000 Latin American children who are blind, 24,000 have ROP. 1 Although ablation of the retina with cryotherapy or laser photocoagulation (standard treatment of ROP) reduces the progression of disease, the visual outcomes after treatment are often poor. 2 9 The Early Treatment for Retinopathy of Prematurity Cooperative Group found that eyes with high-risk prethreshold disease that underwent treatment had better outcomes than those treated after progression to threshold Even with timely treatment of threshold or highrisk prethreshold ROP, retinal detachment cannot be prevented in all cases. Scleral buckling and vitrectomy have both been shown to have some efficacy for treatment of these patients, but there is still some controversy as to the appropriate treatment and timing of intervention for retinal detachment associated with ROP. 9 S19
2 S20 RETINA, THE JOURNAL OF RETINAL AND VITREOUS DISEASES 2008 VOLUME 28 NUMBER 3 Table 1. Systemic and Ophthalmologic Examination Schedule Examination Baseline Injection 24 Hours Complete pediatric evaluation Yes Yes Yes Yes Yes Yes Yes Yes Yes Blood biochemistry analysis Yes No Yes No No Yes No No No Systemic blood pressure Yes Yes Yes Yes No Yes Yes No No determination Vital sign measurement Yes Yes Yes No No No No No No Complete ophthalmic evaluation Yes Yes Yes Yes Yes Yes Yes Yes Yes Fundus photography/video Yes Yes No No No Yes Yes No No (if possible) Fundus drawing Yes No No Yes Yes Yes Yes No No It was previously believed that ROP was associated only with the use of supplemental oxygen in neonates. 13 Currently, however, it is understood that the progression of ROP is multifactorial and may be associated with multiple risk factors. It has also been established that ROP is directly related to the release of angiogenic factors such as vascular endothelial growth factor (VEGF). 14,15 VEGF, which is produced by a variety of cells after hypoxic conditions, is necessary for normal vascular development of the retina and is also a main trigger for neovascularization in proliferative retinopathies During exposure to high levels of oxygen, the premature retina becomes hyperoxic, which reduces the secretion of VEGF, thus inhibiting retinal angiogenesis, particularly in the inner retina where the astrocytes are expressed. When the newborn is returned to normal oxygen exposure, the retina may then become hypoxic subsequent to a lack of normal vessels and the decreased oxygen concentration. Hypoxia induces degeneration of astrocytes that leads to an increase of VEGF; the astrocytes are part of the glia of the internal limiting membrane, and their degeneration allows for the migration of VEGF into the vitreous. Therefore, vascular growth occurs both in the retina and Table 2. Demographic Information for Patients of Patients Demographic Information (n 13) Males 6 (46.15) Females 7 (53.84) Hispanic 13 (100) Birth weight* (g) 1,000 4 (30.76) 1,001 1,499 8 (61.53) 1,500 1 (7.69) Gestational age (wk) (61.53) (38.46) *Mean, 1,233.3 g. Mean, 29.1 wk. outside the retina into the vitreous cavity. 13,15,21,22 Maximum expression of VEGF generally occurs at the border of vascular and avascular retina. This induces rapid neovascularization with abnormal vessels that lack barrier properties. 20 Although ablation of the retina with cryotherapy or laser photocoagulation inhibits the increase in VEGF by destruction of retinal neurons that are the source of VEGF after hypoxia, many patients still have progression to retinal detachment despite conventional therapy. 8,20 The use of anti-vegf therapy for ROP may be justified because it has been demonstrated that in ROP different than in diseases such as neovascular age-related macular degeneration and diabetic retinopathy there is single burst of VEGF that promotes retinal neovascularization. In contrast, in wet agerelated macular degeneration and diabetic retinopathy, there is constant production of VEGF, likely requiring multiple treatments. 23,24 Several VEGF-specific antiangiogenic agents have been approved for use. Bevacizumab (Avastin; Genentech, Inc., South San Francisco, CA), a monoclonal antibody that inhibits the activity of VEGF, is approved for treatment of metastatic colon cancer and is commercially available in Mexico. 20 Currently, there are an increasing number of reports describing the off-label use of bevacizumab for treatment of various proliferative retinopathies with subsequent good visual and structural outcomes Regardless, there is still concern of significant systemic side effects from the use of intravitreal bevacizumab. After a dose of 4 ml to 16 ml of intravenous bevacizumab, a few patients had sudden death, systemic hypertension, and gastrointestinal bleeding. 20 In the vitreous, 2.5 mg (0.1 ml) of bevacizumab is injected, and it has been shown that the systemic absorption is 7.8 ng/ ml, which is the limit of quantification in plasma. This small amount of bevacizumab in the systemic circulation has not been found to be associated with severe systemic side effects. 28
3 ANTIANGIOGENIC THERAPY FOR ROP QUIROZ-MERCADO ET AL S21 Table 3. Distribution of Patients in Three Different Groups on the Basis of Stages of ROP, Emphasizing Attachment of the Retina and Macula of Eyes With Totally Attached Retina With Macula Attached With Macula Detached Unable to Grade Group I 4 (30.76) 3 (23.07) 1 (7.6) Group II 5 (38.46) 5 (38.46) Group III 9 (69.23) 9 (69.23) Group I, 3 patients (4 eyes) with stage IVa or IVb ROP in whom there was no response to conventional treatment; group II, 5 patients (5 eyes) with threshold ROP and poor visualization of the retina; group III, 5 patients (9 eyes) who had high-risk prethreshold or threshold ROP. We present our experience with the off-label use of intravitreal bevacizumab for treatment of ROP. Methods We performed an observational, prospective, noncomparative, interventional case series including premature or low-birth-weight infants who had new vessels or abnormal vessels identified and were treated with intravitreal injections of bevacizumab. The infants presented with the following clinical findings by routine ophthalmoscopy 4 weeks to 6 weeks after birth: stage III ROP plus disease, high-risk prethreshold ROP, threshold ROP, stage IVa or IVb ROP, or inadequate dilatation or poor visualization of the fundus. Eyes with new vessels in the vitreous cavity or at the retinal periphery were included as well as eyes with persistent fetal vasculature in the anterior segment. All patients were divided in three different groups: group I, patients with stage IVa or IVb ROP in whom there was no response to conventional treatment (laser photocoagulation or cryotherapy); group II, patients with threshold ROP for whom visualization of the retina was poor, therefore making treatment with laser or cryotherapy difficult; and group III, patients with high-risk prethreshold or threshold ROP. The patients were recruited between September 2005 and July ,30 Exclusion criteria included leukokoria not secondary to ROP, presence of other ophthalmologic conditions at the time of diagnosis, and absence of either active new vessels or abnormal vessels. Worsening of the systemic condition led to withdraw from the study. Ocular inflammation or infection at the time of the diagnosis was a relative contraindication. The protocol was reviewed and approved by the Ethics Committee of the Asociacion para Evitar la Ceguera en México (Mexico City), and informed consent was obtained under Mexican law regulations (Norma Oficial Mexicana NOM 168 del Expediente Clinico). The treatment was administered during general anesthesia. Each intravitreal bevacizumab injection was performed as follows. The patient was prepped with sterile povidone iodine solution around the eye to be injected. A lid speculum was used to retract the lids, and two to three drops of 5% povidone iodine were placed on the eye to be injected. Using a Castroviejo caliper (Jorgensen Laboratories, Loreland, CO), 2 mm was measured posterior to the limbus in the inferotemporal quad- ROP Table 4. Group I: Three Patients (Four Eyes) With Stage IVa or IVb ROP Who Had No Response to Conventional Treatment Preinjection, 4 s, 12 s, 38 s, None 2 (15.38) 2 (15.38) Stage I 2 (15.38) Stage II Stage III Stage IVa 3 (23.07) Vitrectomy, 1 (7.6) Retina attached, 1 (7.6) Retina attached, 1 (7.6) Stage IVb 1 (7.6) Vitrectomy, 1 (7.6) Retina attached, 1 (7.6) Retina attached, 1 (7.6) Retinal detachments were classified as stage IVa in 3 eyes (23.07%) and stage IVb in 1 eye (7.6%). Four weeks after intravitreal injection of bevacizumab, 2 eyes (15.38%) had improvement, and at 12 weeks and 38 weeks, complete regression of neovascularization was observed. Two eyes (15.38%) required vitrectomy due to persistent retinal detachment with stage IVa ROP and stage IVb ROP. At subsequent visits, the retina was noted to be reattached in both eyes.
4 S22 RETINA, THE JOURNAL OF RETINAL AND VITREOUS DISEASES 2008 VOLUME 28 NUMBER 3 ROP Table 5. Group II: Five Patients (Five Eyes) With Threshold ROP and Poor Visualization of the Retina Preinjection, 4 s, 12 s, 38 s, Regressed 5 (38.46) 5 (38.46) Stage I 4 (30.76) Stage II Stage III plus disease, prethreshold, 1 (7.60) and threshold Unable to grade 5 (38.46) Poor visualization was secondary to persistent tunica vasculosa lentis that prevented mydriasis. One week after intravitreal injection, we were able to classify 4 patients (30.76%) as having stage II ROP after complete mydriasis. After 4 weeks, we found that these four patients had had regression of ROP. In all patients in this group, we observed involution of tunica vasculosa lentis. rant; 0.05 ml (1.25 mg) of bevacizumab was then injected at this location with a 27-gauge needle. Anterior chamber paracentesis was performed to achieve appropriate intraocular pressure. 28,31 33 We performed close follow-up of the patients to determine systemic status and ophthalmologic findings (Table 1). Results Thirteen consecutive patients (18 eyes; 6 males and 7 females) were included in the study. Mean gestational age was 29.1 weeks (range, weeks), and mean birth weight was 1,233.3 g (range, 900 1,600 g). Mean age at the time of intravitreal treatment was 2.3 months (range, 1 4 months), and minimum follow-up was 6 months. Demographic data are listed in Table 2. The groups were distributed as follows: group I, 3 patients (4 eyes) with stage IVa or IVb ROP in whom there was no response to conventional treatment; group II, 5 patients (5 eyes) with threshold ROP and poor visualization of the retina; and group III, 5 patients (9 eyes) who had high-risk prethreshold or threshold ROP. None of the patients received laser treatment after bevacizumab injection. The distribution of the patients in the different groups is listed in Table 3. We measured neovascularization by clock hours and by zones as indicated in the International Classification of Retinopathy of Prematurity. 29 The structural outcomes of the three groups are listed and explained in Tables 4 6. We found neovascular regression in all patients, with one patient who had stage IVa ROP having spontaneous retinal reattachment after intravitreal injection of bevacizumab (Fig. 1). Fundus photography and video of the fundus were not always possible, but careful drawings of anatomical findings were obtained. Reinjection was not necessary during a 6-month follow up. There were no serious ocular or systemic adverse events in any case. Discussion The main findings of our study are that intravitreal injection of bevacizumab effectively inhibits neovascularization in ROP with no adverse systemic or ocular side effects. We also observed regression of tunica vasculosa lentis 34 (Fig. 2). In an animal model, we observed that antiangiogenic therapy with prolactin (16 kd) induces apoptosis of fetal vasculature. 35 The association of persistent fetal vasculature with ROP is well known, and apoptosis of the vascular system may be affected. 34 In group II, the anatomy of the eye may have been improved by regression of persistent fetal vasculature with induction of apoptosis (Fig. 3). ROP Table 6. Group III: Five Patients (Nine Eyes) Who Had High-Risk Prethreshold or Threshold ROP Preinjection, 4 s, 12 s, 38 s, None 9 (69.23) 9 (69.23) Stage I 9(69.23) Stage II Stage III plus disease, prethreshold, and threshold 9 (69.23) After treatment, we observed that ROP regressed from stage III to stage I 1 week later. At week 12, we found complete vascularization of the avascular retina.
5 ANTIANGIOGENIC THERAPY FOR ROP QUIROZ-MERCADO ET AL S23 Fig. 1. Case 1. Patient from group I. A, Baseline photograph showing retinal temporal detachment and active neovascularization (arrow). B, One week after treatment, we observed a decrease of neovascularization, but the retina was still detached (arrow). C, At week 4, it was evident only as a nonvascularized fibrous membrane (arrow). D, At week 12, we observed retinal reattachment without neovascularization (arrow). Fig. 2. Case 2. Patient from group II. A, We were not able observe mydriasis due to tunica vasculosa lentis in the anterior segment (arrow). B, Five days after bevacizumab injection, we observed mydriasis; there were still some vessels (arrow), but they involuted completely during week 2.
6 S24 RETINA, THE JOURNAL OF RETINAL AND VITREOUS DISEASES 2008 VOLUME 28 NUMBER 3 Fig. 3. Case 3. Patient who was enrolled in two different groups: group I for the right eye and group II for the left eye. Both eyes presented with regression of pathologic neovascularization and of persistent fetal vasculature in the anterior segment. Two weeks later, he had stage I retinopathy of prematurity. One month later, retinal vessels reached zone 3. ROP is a disease in need of better therapy. 29,30,36,37 It occurs in premature infants and remains a leading cause of vision impairment in children younger than 6 years of age. Although cryotherapy and laser ablation of avascular retina improve the chances for good outcome, 30% of infants with threshold ROP will develop a retinal detachment and blindness. More than 80% of infants who develop threshold ROP have visual acuity of 20/60 or worse, even when the retina remains attached (with an abnormal retinal structure that persists into adulthood). 4 6 With our current knowledge, it would seem that ROP may be an ideal disease model to treat with antiangiogenic therapy because it occurs in early development (occurring only during a short period) and affects an immunologically privileged part of the body. Progression to high-risk prethreshold or threshold ROP occurs during a narrow window of time, and the time from the onset of pathologic neovascularization to devastating retinal detachment is usually measured in weeks. Clearly, for this disease, antiangiogenic therapy has a fighting chance to succeed. 29 There is concern, however, that antiangiogenic therapy for infants may affect abnormal vascular development; however, in an animal model, it has been demonstrated that a single injection of recombinant human VEGF 165 b peptide can significantly reduce preretinal neovascularization without exacerbation of inner retinal ischemia because it permits physiologic angiogenesis to proceed normally and with no interference to the normal development of photoreceptors or other cells in the eye In addition, with the specificity of monoclonal antibody to VEGF, we may very possibly avoid these collateral effects, such as alteration of photoreceptor cell development or downregulation of factors that contribute to healthy blood vessel formation. We believe that the findings of this study move us closer to better treatment of ROP. Intravitreal injection of bevacizumab may be promising for treatment of patients with ROP. However, further studies need to be performed to determine the timing, safety, and long-term efficacy of intravitreal bevacizumab for treatment of ROP either as first-line therapy with or without laser or after failure of conventional therapy. Key words: antiangiogenic therapy, bevacizumab, retinopathy of prematurity, persistent fetal vasculature. References 1. Gilbert C, Rahi J, Eckstein M, et al. Retinopathy of prematurity in middle-income countries. Lancet 1997;350: Chang-Ling T, Stone J. Retinopathy of prematurity: its origins in the architecture of the retina. Prog Retinal Eye Res 1993;12: Hutchenson KA, Kelly A. Retinopathy of prematurity. Curr Opin Ophthalmol 2003;14: Earl A, Palmer MD, John T, et al. Incidence and early course of retinopathy of prematurity. Ophthalmology 1991;98: Early Treatment for Retinopathy of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy of prematurity: results of the Early Treatment for Retinopathy of Prematurity Study Randomized Trial. Arch Ophthalmol 2003;121: Repka Michael X, Tung BMS, Good W. Outcome of eyes developing retinal detachment during the Early Treatment for Retinopathy of Prematurity Study (ETROP). Arch Ophthalmol 2006;124: Cryotherapy for Retinopathy of Prematurity Cooperative Group. Multicenter trial of cryotherapy for retinopathy of prematurity; ophthalmological outcome 10 years. Arch Ophthalmol 2001;119: Harnet ME, Mc Colm JR. Diode laser for ROP. Ophthalmology 2005;112: Early Treatment for Retinopathy of Prematurity Cooperative Group. Revised indications for the treatment of retinopathy
7 ANTIANGIOGENIC THERAPY FOR ROP QUIROZ-MERCADO ET AL S25 of prematurity. Results of The Early Treatment for Retinopathy of Prematurity Randomized Trial. Arch Ophthalmol 2003;121: Cuthbertson F, Nerwsom R. UK retinopathy of prematurity treatment survey. Eye 2006;7: Tufail A, Singh AJ, Haynes RJ, Dodd RJ. Late onset vitreoretinal complications of regressed retinopathy of prematurity. Br J Ophthalmol 2004;88: Fielder AR, Shaw ED, Robinson J, Yin K. Natural history of retinopathy of prematurity: a prospective study. Eye 1992;6: Penn JS, Tolman BL, Lowery LA. Variable oxygen exposure causes preretinal neovascularization in the newborn rat. Invest Ophthalmol Vis Sci 1993;34: Madan A. Angiogenesis and antiangiogenesis in the neonate: relevance to retinopathy of prematurity. Neoreviews 2003;4: Villegas B, González F, Fernández M. Growth factor levels and ROP. Ophthalmology 2005;112: Stone J, Itim A, Alon T, et al. Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. J Neurosci 1995;15: Alon T, Hemo I, Itin A, et al. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1995;1: Stone J, Chang-Ling T, Pe er J, et al. Roles of vascular endothelial growth factor and astrocyte degeneration in the genesis of retinopathy of prematurity. Invest Ophthalmol Vis Sci 1996;37: Ferrara N, Gerber HP, Lde Couter J. The biology of VEGF and its receptors. Nat Med 2003;9: FDA Approves First Angiogenesis Inhibitor to Treat Colorectal Cancer. For immediate release P February 26, Hollander H, Makarov F, Dreher Z, et al. Functions of the macroglia of the retina: the sharing and division of labour between astrocytes and Muller cells. J Comp Neurol 1991; 313: Wilson C, Theodoru M, Cocker KD, Fielder A. The temporal retinal blood vessels and preterm birth. Br J Ophthalmol 2006;7: Lashkari K, Hirose T, Yazdany J, et al. Vascular endothelial growth and hepatocyte growth factor levels are differentially elevated in patients with advanced retinopathy of prematurity. Am Pathol 2000;156: Hughes S, Yang H, Chan-ling T. Vascularization of the human fetal retina: roles of vasculogenesis and angiogenesis. Invest Ophthalmol Vis Sci 2000;41: Rich RM, Rosenfeld PJ, Puliafito CA, et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 2006;26: Abraham-Marin ML, Cortez-Luna C, Alvarez-Rivera G, et al. Intravitreal bevacizumab therapy for neovascular agerelated macular degeneration: a pilot study. Graefes Arch Clin Exp Ophthalmol September 28, 2006 [Epub ahead]. 27. Ustariz-Gonzalez O, Martinez-Castellanos M, Gordon M, Quiroz-Mercado H. Antiangiogenesis. Rev Mex Oftalmol 2006;80: Konopatskaya O, Churchill A, Harper SJ, et al. VEGF 165b, an endogenous C-terminal splice variant of VEGF, inhibits retinal neovascularization in mice. Mol Vis 2006;12: Committee for the Classification of Retinopathy of Prematurity. An international classification of retinopathy of prematurity. II, The classification of retinal detachment. Arch Ophthalmol 1987;105: Pierce EA, Foley ED, Smith LEH. Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity. Arch Ophthalmol 1996;114: Aiello LP, Brucker AJ, Chang S, et al. Evolving guidelines for intravitreous injections. Retina 2004;24:S3 S Trese MT. A two hand dissection technique during closed vitrectomy for retinopathy of prematurity. Am J Ophthalmol 1986;101: International Committee for the Classification of Retinopathy of Prematurity. An international classification of retinopathy of prematurity (special article). Pediatrics 1984;74: Goldberg M. Persistent fetal vasculature (PFV): an integrated interpretation of signs and symptoms associated with persistent hyperplasic primary vitreous (PHPV). LIV Edward Jackson Memorial Lecture. AJO 1997;124: Dueñas Z, Rivera J, Quiroz-Mercado H, et al. Prolactin in eyes of patients with retinopathy of prematurity: implications for vascular regression. Invest Ophthalmol Vis Sci 2004;45: Aiello LP, Pierce EA, Foley ED, et al. Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA 1995;92: Robbins SG, Rajaratman VS, Penn JS. Evidence for upregulation and redistribution of vascular endothelial growth factor (VEGF) receptor flt-1 and flk-1 in the oxygen-injured rat retina. Growth Factors 1998;16: Hellstrom A, Perruzi C, Ju M, et al. Low IGF-I suppresses VEGF-survival signalling in retinal endothelial cells: direct correlation with clinical retinopathy of prematurity. Proc Natl Acad Sci USA 2001;98: Quiroz-Mercado H, Martinez-Castellanos MA, Hernandez- Rojas M. Security and efficacy of intravitreal bevacizumab in retinopathy of prematurity in previously treated patients. Presented at Cannes Retina Festival; September 13, Partially published in Seminar in Opthalmology 2007;22:
OFF-LABEL USE OF INTRAVITREAL BEVACIZUMAB (AVASTIN) FOR SALVAGE TREATMENT IN PROGRESSIVE THRESHOLD RETINOPATHY OF PREMATURITY
OFF-LABEL USE OF INTRAVITREAL BEVACIZUMAB (AVASTIN) FOR SALVAGE TREATMENT IN PROGRESSIVE THRESHOLD RETINOPATHY OF PREMATURITY GEETA A. LALWANI, MD, AUDINA M. BERROCAL, MD, TIMOTHY G. MURRAY, MD, MBA, MARIA
More informationRetinopathy of prematurity (ROP) is a disorder of retinal
INVITED COMMENTARY Retinopathy of Prematurity Alice L. Bashinsky Retinopathy of prematurity (ROP) is a vasoproliferative retinal disorder unique to premature infants. As premature births increase in many
More informationLaser Therapy Versus Anti-VEGF Agents for Treatment of Retinopathy of Prematurity. Ilya Leskov, MD, PhD Shizuo Mukai, MD
Laser Therapy Versus Anti-VEGF Agents for Treatment of Retinopathy of Prematurity Ilya Leskov, MD, PhD Shizuo Mukai, MD Introduction Retinopathy of prematurity (ROP) is characterized by abnormal retinal
More informationOcular Assessment. Materials and Methods
LONG-TERM EFFECT OF ANTIANGIOGENIC THERAPY FOR RETINOPATHY OF PREMATURITY Up to 5 Years of Follow-up MARÍA A. MARTÍNEZ-CASTELLANOS, MD,* SHULAMIT SCHWARTZ, MD, MYRIAM L. HERNÁNDEZ-ROJAS, MD,* VERONICA
More informationINFANTS WITH birth weights less
CLINICAL SCIENCES of Retinopathy of Prematurity Michael X. Repka, MD; Earl A. Palmer, MD; Betty Tung, MS; for the Cryotherapy for Retinopathy of Prematurity Cooperative Group Objective: To report the timing
More informationRetinopathy of Prematurity. Objectives. Normal Retina Development. ROP Pathogenesis 6/8/2018. Thomas W. Hejkal, MD, PhD Eye Consultants, PC
Retinopathy of Prematurity Thomas W. Hejkal, MD, PhD Eye Consultants, PC Chair Emeritus Department of Ophthalmology UNMC drhejkal@eyeconsultantspc.com (No commercial interests) Objectives Identify risk
More informationIntravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity
Major Articles Intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity Janice C. Law, MD, Franco M. Recchia, MD, David G. Morrison, MD, Sean P. Donahue, MD, PhD, and Robert L. Estes,
More informationMulticenter Study of Cryotherapy for Retinopathy of Prematurity (CRYO-ROP) Publications
Multicenter Study of Cryotherapy for Retinopathy of Prematurity (CRYO-ROP) Publications Bartholomew PA, Chao J, Evans JL, Hammel AM, Trueb AL, Verness JL, Dobson V, Quinn GE. Acceptance/Use of the Teller
More informationEarly Human Development
Early Human Development 88 (2012) 937 941 Contents lists available at SciVerse ScienceDirect Early Human Development journal homepage: www.elsevier.com/locate/earlhumdev Treatment of retinopathy of prematurity
More informationFINAL RESULTS OF THE EARLY TREATMENT FOR RETINOPATHY OF PREMATURITY (ETROP) RANDOMIZED TRIAL
FINAL RESULTS OF THE EARLY TREATMENT FOR RETINOPATHY OF PREMATURITY (ETROP) RANDOMIZED TRIAL BY William V. Good MD,* on behalf of the Early Treatment for Retinopathy of Prematurity Cooperative Group ABSTRACT
More informationScreening Examination of Premature Infants for Retinopathy of Prematurity
Screening Examination of Premature Infants for Retinopathy of Prematurity (1) Overview material Release Date 2006 Status Available in Electronic Format Available in Print Format Bibliographic citation
More informationStudy of Incidence, Clinical Staging and Risk Factors of Retinopathy of Prematurity in Rural Area
Original Article Study of Incidence, Clinical Staging and Risk Factors of Retinopathy of Prematurity in Rural Area Neeraj Gupta, Narendra P Datti, *Beeregowda Y, Kanthamani Krishnappa, Krishnamurthy D
More informationBevacizumab and ROP: Review of an RCT. M Chakraborty UHW
Bevacizumab and ROP: Review of an RCT M Chakraborty UHW Sections ROP VEGF and its involvement in the pathogenesis of ROP Details of the study (BEAT-ROP) Methods Results Conclusions Limitations/controversies
More informationClassification of ROP
Classification of ROP Thomas Lee 2 Keywords Retinopathy of prematurity (ROP) Threshold ROP Plus disease Neovascularization Avascular retina Retinopathy of prematurity (ROP) is an iatrogenic disease. Prior
More informationEFFICACY OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS IN RETINAL DISORDER FOR BETTER VISUAL ACUITY
EFFICACY OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS IN RETINAL DISORDER FOR BETTER VISUAL ACUITY Diwakar chaudhary *1, 2, Hu shuqiong, Long Yuan and Xiong kun 1 Yangtze University, 1 Nanhuan Road
More informationOcular Complications after Intravitreal Bevacizumab Injection in Eyes with Choroidal and Retinal Neovascularization
Original Article Ocular Complications after Intravitreal Bevacizumab Injection in Eyes with Choroidal and Retinal Neovascularization Aimal Khan, P.S Mahar, Azfar Nafees Hanfi, Umair Qidwai Pak J Ophthalmol
More informationAge-related macular degeneration (AMD) and RANIBIZUMAB (Lucentis)
Aggiornamento biotecnologico: MoAb anti VEGF Age-related macular degeneration (AMD) and RANIBIZUMAB (Lucentis) Giulia Germena AMD DRY (non-neovascular) Atrophic cell death in the macula No leakage WET
More informationChildhood blindness due to ROP
Childhood blindness due to ROP Number of blind children/10 million pop, by cause and level of development Proportion of blindness due to ROP, by World Bank region Estimates of numbers blind from ROP, by
More information10. ADVANCED RETINOPATHY OF PREMATURITY
Guidelines to be followed by centres, services and units in order to be designated as Reference Centres, Services and Units of the National Health System as agreed by the Interterritorial Board. 10. ADVANCED
More informationPros and Cons in the use of AntiVEGF therapy in ROP
MEDICAL SCHOOL FEDERAL UNIVERSITY OF RIO GRANDE DO SUL PORTO ALEGRE BRAZIL Pros and Cons in the use of AntiVEGF therapy in ROP João Borges Fortes Filho MD, PhD Professor of Ophthalmology DESPITE THE GREATER
More informationRETINOPATHY OF PREMATURITY (ROP) IS A RETINAL
Intravitreal Bevacizumab for Retinopathy of Prematurity: Refractive Error Results BJÖRN C. HARDER, FRANK C. SCHLICHTENBREDE, STEFAN VON BALTZ, WALDEMAR JENDRITZA, BETTINA JENDRITZA, AND JOST B. JONAS PURPOSE:
More informationRetinopathy of Prematurity Current Trends and Advances. Susmito Biswas Consultant Paediatric Ophthalmologist Manchester Royal Eye Hospital
Retinopathy of Prematurity Current Trends and Advances Susmito Biswas Consultant Paediatric Ophthalmologist Manchester Royal Eye Hospital Preventative strategies Neonatal care Oxygen management Optimising
More informationNon-ophthalmologist screening for retinopathy of prematurity
130 Br J Ophthalmol 2000;84:130 134 ORIGINAL ARTICLES Clinical science N Edgar Miles Center for Pediatric Ophthalmology, Storm Eye Institute, Medical University of South Carolina, Charleston, South Carolina
More informationDiode Laser Photocoagulation for Retinopathy of Prematurity: Outcomes After 7 Years of Treatment
Diode Laser Photocoagulation for Retinopathy of Prematurity: Outcomes After 7 Years of Treatment Simona-Delia Nicoara; Cristina Cristian, MD; Iulian Irimescu, MD; Anne-Claudia Stefanut, MD, PhD; Gabriela
More informationDiagnosis and treatment of diabetic retinopathy. Blake Cooper MD Ophthalmologist Vitreoretinal Surgeon Retina Associates Kansas City
Diagnosis and treatment of diabetic retinopathy Blake Cooper MD Ophthalmologist Vitreoretinal Surgeon Retina Associates Kansas City Disclosures Consulted for Novo Nordisk 2017,2018. Will be discussing
More informationCLINICAL SCIENCES. Rajeev H. Muni, MD, FRCSC; Radha P. Kohly, MD, FRCSC, PhD; Alexander C. Charonis, MD; Thomas C. Lee, MD
CLINICL SCIENCES Retinoschisis Detected With Handheld Spectral-Domain Optical Coherence Tomography in Neonates With dvanced Retinopathy of Prematurity Rajeev H. Muni, MD, FRCSC; Radha P. Kohly, MD, FRCSC,
More informationInternational Journal of Health Sciences and Research ISSN:
International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article A Multivariate Analysis of Intravitreal Injection of Anti-VEGF Bevacizumab in the Treatment
More informationClinical Study Macular Development in Aggressive Posterior Retinopathy of Prematurity
BioMed Research International Volume 2015, Article ID 808639, 5 pages http://dx.doi.org/10.1155/2015/808639 Clinical Study Macular Development in Aggressive Posterior Retinopathy of Prematurity Hemang
More informationIntravitreal bevacizumab for pediatric exudative retinal diseases
Saudi Journal of Ophthalmology (2011) 25, 193 197 King Saud University Saudi Journal of Ophthalmology www.saudiophthaljournal.com www.ksu.edu.sa www.sciencedirect.com ORIGINAL ARTICLE Intravitreal bevacizumab
More information3/6/2014. None relevant to this talk. Michael Trese Associated Retinal Consultants Royal Oak, Michigan USA
None relevant to this talk Michael Trese Associated Retinal Consultants Royal Oak, Michigan USA Chicago March 2014 Whenever a drug is used with a Different dose than in the label larger or smaller Different
More informationROP. Therapies. Current. Randomizing infants to receive either retinal laser or intravitreal. How Laser and Anti-VEGF Compare
Current ROP How Laser and Anti-VEGF Compare Therapies With the publication of the BEAT-ROP study results in 2011, some clinicians were inclined to jump on the bevacizumab bandwagon, while others held back,
More informationGrand Rounds. Jenny Temnogorod SUNY Downstate Medical Center Department of Ophthalmology September 19, 2013
Grand Rounds Jenny Temnogorod SUNY Downstate Medical Center Department of Ophthalmology September 19, 2013 History and Examination HPI: 2 day old SGA (small for gestational age, 37 weeks, BWt. 1760g) with
More informationTHE ROLE OF anti-vegf IN DIABETIC RETINOPATHY AND AGE RELATED MACULAR DEGENERATION
THE ROLE OF anti-vegf IN DIABETIC RETINOPATHY AND AGE RELATED MACULAR DEGENERATION MOESTIDJAB DEPARTMENT OF OPHTHALMOLOGY SCHOOL OF MEDICINE AIRLANGGA UNIVERSITY DR SOETOMO HOSPITAL SURABAYA INTRODUCTION
More informationLong-Term Visual Outcome in Proliferative Diabetic Retinopathy Patients After Panretinal Photocoagulation
Long-Term Visual Outcome in Proliferative Diabetic Retinopathy Patients After Panretinal Photocoagulation Murat Dogru, Makoto Nakamura, Masanori Inoue and Misao Yamamoto Department of Ophthalmology, Kobe
More informationIndex. Note: Page numbers with f and t indicate figures and tables, respectively.
Index Note: Page numbers with f and t indicate figures and tables, respectively. A Action Plan on Eye Health VISION 2020 Latin America, 140 Aggressive posterior retinopathy of prematurity (APROP), 21,
More informationLate-onset Retinal Detachment Associated with Regressed Retinopathy of Prematurity
Late-onset Retinal Detachment Associated with Regressed Retinopathy of Prematurity Hiroko Terasaki*, and Tatsuo Hirose* *Schepens Retina Associates, Schepens Eye Research Institute, Harvard Medical School,
More informationVascular changes on fluorescein angiography of premature infants with low risk of retinopathy of prematurity after high oxygen exposure
DOI 10.1186/s40942-016-0055-6 International Journal of Retina and Vitreous ORIGINAL ARTICLE Open Access Vascular changes on fluorescein angiography of premature infants with low risk of retinopathy of
More informationClinically Significant Macular Edema (CSME)
Clinically Significant Macular Edema (CSME) 1 Clinically Significant Macular Edema (CSME) Sadrina T. Shaw OMT I Student July 26, 2014 Advisor: Dr. Uwaydat Clinically Significant Macular Edema (CSME) 2
More informationPulsed mode versus near-continuous mode delivery of diode laser photocoagulation for high-risk retinopathy of prematurity
Pulsed mode versus near-continuous mode delivery of diode laser photocoagulation for high-risk retinopathy of prematurity Evelyn A. Paysse, MD, a,b Mohamed A.W. Hussein, MD, a Aaron M. Miller, MD, a Kathryn
More informationDiabetic Retinopathy
Diabetic Retinopathy Diabetes mellitus is one of the leading causes of irreversible blindness worldwide. In the United States, it is the most common cause of blindness in people younger than 65 years.
More informationRETINOPATHY OF PREMATUrity
CLINICAL SCIENCES Longitudinal Postnatal Weight Measurements for the Prediction of Retinopathy of Prematurity Carolyn Wu, MD; Deborah K. VanderVeen, MD; Ann Hellström, MD, PhD; Chatarina Löfqvist, PhD;
More informationINFORMED CONSENT FOR AVASTIN TM (BEVACIZUMAB) INTRAVITREAL INJECTION
INFORMED CONSENT FOR AVASTIN TM (BEVACIZUMAB) INTRAVITREAL INJECTION INDICATIONS: Age-related macular degeneration (AMD) is the leading cause of blindness in people over 50 years of age. It is caused by
More informationOverview. Retinal vascularisation during development. Classification of ROP. Visual loss from retinopathy of prematurity: first global estimates
Visual loss from retinopathy of prematurity: first global estimates Overview ROP - the condition, risk factors and control ROP as a cause of visual loss Earlier estimates New global estimates MARCH seminar,
More informationA bs tr ac t. n engl j med 364;7 nejm.org february 17,
The new england journal of medicine established in 1812 february 17, 2011 vol. 364 no. 7 Efficacy of for Stage 3+ Retinopathy of Prematurity Helen A. Mintz-Hittner, M.D., Kathleen A. Kennedy, M.D., M.P.H.,
More informationPMA Weight (g) Diagnosis at IVB. at IVB
1 Klinik Mata Nusantara, Jakarta, Indonesia 2 Department of Ophthalmology, Princess Margaret Hospital for Children, University of Western Australia, Perth, Australia 3 Department of Ophthalmology, Sakai
More informationPathogenesis of retinopathy of prematurity
Growth Hormone & IGF Research 14 (2004) S140 S144 www.elsevier.com/locate/ghir Pathogenesis of retinopathy of prematurity Lois E.H. Smith * Department of Ophthalmology, Children s Hospital, Harvard Medical
More informationAntivascular endothelial growth factor for retinopathy of prematurity Helen A. Mintz-Hittner a and Leah M. Best b
Antivascular endothelial growth factor for retinopathy of prematurity Helen A. Mintz-Hittner a and Leah M. Best b a Department of Ophthalmology and Visual Science, University of Texas Health Science Center,
More informationEyePACS Grading System (Part 3): Detecting Proliferative (Neovascular) Diabetic Retinopathy. George Bresnick MD MPA Jorge Cuadros OD PhD
EyePACS Grading System (Part 3): Detecting Proliferative (Neovascular) Diabetic Retinopathy George Bresnick MD MPA Jorge Cuadros OD PhD Anatomy of the eye: 3 Normal Retina Retinal Arcades Macula Optic
More informationThe retinal renin-angiotensin system: implications for therapy in diabetic retinopathy
(2002) 16, S42 S46 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh : implications for therapy in diabetic retinopathy AK Sjølie 1 and N Chaturvedi 2 1 Department
More informationCriteria for the timing of the initial retinal examination to screen for retinopathy of prematurity
VOL. 35 NO. PHILIPPINE JOURNAL OF Ophthalmology JANUARY ORIGINAL ARTICLE JUNE 00 Milagros H. Arroyo, MD, MPH - Dino L. Camonias, MD Andrea Kristina Monzon-Pajarillo, MD Farlah Angela M. Salvosa-Sevilla,
More informationCURRICULUM VITAE. (713) (O) B.S. in Biology, Fu-Jen Catholic University, Taiwan, R.O.C., 1974
CURRICULUM VITAE NAME: Betty P. Tung BIRTH DATE: November 23, 1951 OFFICE (713) 500-9549(O) Betty.p.tung@uth.tmc.edu EDUCATIONAL BACKGROUND: B.S. in Biology, Fu-Jen Catholic University, Taiwan, R.O.C.,
More informationTESTING INTRAVITREAL TOXICITY OF BEVACIZUMAB (AVASTIN)
TESTING INTRAVITREAL TOXICITY OF BEVACIZUMAB (AVASTIN) ROBERTA P. A. MANZANO, MD, GHOLAM A. PEYMAN, MD, PALWASHA KHAN, MD, MUHAMET KIVILCIM, MD Purpose: To evaluate the retinal toxicity of varying doses
More informationmeasure of your overall performance. An isolated glucose test is helpful to let you know what your sugar level is at one moment, but it doesn t tell you whether or not your diabetes is under adequate control
More informationOphthalmic VEGF Inhibitors. Eylea (aflibercept), Macugen (pegaptanib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Ophthalmic VEGF Inhibitors Page: 1 of 5 Last Review Date: September 20, 2018 Ophthalmic VEGF Inhibitors
More informationA Patient s Guide to Diabetic Retinopathy
Diabetic Retinopathy A Patient s Guide to Diabetic Retinopathy 840 Walnut Street, Philadelphia PA 19107 www.willseye.org Diabetic Retinopathy 1. Definition Diabetic retinopathy is a complication of diabetes
More informationClinical Study Posterior Pole Sparing Laser Photocoagulation Combined with Intravitreal Bevacizumab Injection in Posterior Retinopathy of Prematurity
Ophthalmology, Article ID 257286, 5 pages http://dx.doi.org/10.1155/2014/257286 Clinical Study Posterior Pole Sparing Laser Photocoagulation Combined with Intravitreal Bevacizumab Injection in Posterior
More informationClinical Study Inhalation Anesthesia with Sevoflurane during Intravitreal Bevacizumab Injection in Infants with Retinopathy of Prematurity
BioMed Research International Volume 2013, Article ID 435387, 4 pages http://dx.doi.org/10.1155/2013/435387 Clinical Study Inhalation Anesthesia with Sevoflurane during Intravitreal Bevacizumab Injection
More informationROLE OF LASER PHOTOCOAGULATION VERSUS INTRAVITREAL TRIAMCINOLONE ACETONIDE IN ANGIOGRAPHIC MACULAR EDEMA IN DIABETES MELLITUS
ORIGINAL ARTICLE ROLE OF LASER PHOTOCOAGULATION VERSUS INTRAVITREAL TRIAMCINOLONE ACETONIDE IN ANGIOGRAPHIC MACULAR EDEMA IN DIABETES MELLITUS Aggarwal Somesh VP 1, Shah Sonali N 2, Bharwada Rekha M 3,
More informationPART 1: GENERAL RETINAL ANATOMY
PART 1: GENERAL RETINAL ANATOMY General Anatomy At Ora Serrata At Optic Nerve Head Fundoscopic View Of Normal Retina What Is So Special About Diabetic Retinopathy? The WHO definition of blindness is
More informationEarly retinopathy of prematurity findings identified with fluorescein angiography
Graefes Arch Clin Exp Ophthalmol (2013) 251:2093 2097 DOI 10.1007/s00417-013-2321-8 RETINAL DISORDERS Early retinopathy of prematurity findings identified with fluorescein angiography L. Consuelo Zepeda-Romero
More informationEFFICACY OF INTRAVITREAL TRIAMCINOLONE ACETONIDE FOR THE TREATMENT OF DIABETIC MACULAR EDEMA
Basrah Journal Of Surgery EFFICACY OF INTRAVITREAL TRIAMCINOLONE ACETONIDE FOR THE TREATMENT OF DIABETIC MACULAR EDEMA Salah Zuhair Abed Al-Asadi MB,ChB, FICMS, Lecturer, Department of Surgery, College
More informationProtocol. This trial protocol has been provided by the authors to give readers additional information about their work.
Protocol This trial protocol has been provided by the authors to give readers additional information about their work. Protocol for: Mintz-Hittner HA, Kennedy KA, Chuang AZ. Efficacy of intravitreal bevacizumab
More informationDiabetic Retinopathy. Barry Emara MD FRCS(C) Giovanni Caboto Club October 3, 2012
Diabetic Retinopathy Barry Emara MD FRCS(C) Giovanni Caboto Club October 3, 2012 Outline Statistics Anatomy Categories Assessment Management Risk factors What do you need to do? Objectives Summarize the
More informationPlease check appropriate box: Right Left. Bilateral Not Applicable
UNIVERSITY MEDICAL CENTER DISCLOSURE AND CONSENT - MEDICAL AND SURGICAL PROCEDURES TO THE PATIENT: You have the right as a patient to be informed about your condition and the recommended surgical, medical
More informationEyes on Diabetics: How to Avoid Blindness in Diabetic Patient
Eyes on Diabetics: How to Avoid Blindness in Diabetic Patient Rova Virgana FK Unpad Pusat Mata Nasional RS Mata Cicendo Bandung Eye Center (Hospital and Clinic) PIT IDI Jabar 2018 Keys Facts from WHO
More informationAnti VEGF Agents in Retinal Disorders Current Scenario
Retina Anti VEGF Agents in Retinal Disorders Current Scenario Charu Gupta MS Charu Gupta MS, Cyrus M. Shroff MD Shroff Eye Centre, New Delhi T is a group of proteins involved in the regulation of angiogenesis,
More informationMANAGEMENT OF NEOVASCULAR GLAUCOMA
MSO EXPRESS: ISSUE 3 MANAGEMENT OF NEOVASCULAR GLAUCOMA Associate Professor Dr. Norlina Mohd Ramli, Dr. Ng Ker Hsin Associate Professor Dr. Norlina Mohd Ramli MBBS (UK) MRCOphth (UK) MS Ophthal (Mal) Fellowship
More informationApplications of Sustained Release Delivery Systems in Ocular Disease
Applications of Sustained Release Delivery Systems in Ocular Disease Formulation and Delivery Systems For Peptide and Protein 2012 December 5, 2012 Christopher A. Rhodes, Ph.D. Principal, Christopher A
More informationDiabetic Retinopathy A Presentation for the Public
Diabetic Retinopathy A Presentation for the Public Ray M. Balyeat, MD The Eye Institute Tulsa, Oklahoma The Healthy Eye Light rays enter the eye through the cornea, pupil and lens. These light rays are
More informationSurgical Results and Visual Outcomes of Vitreous Surgery for Advanced Stages of Retinopathy of Prematurity
Surgical Results and Visual Outcomes of Vitreous Surgery for Advanced Stages of Retinopathy of Prematurity Toshihiro Kono, Kenji Oshima and Yuki Fuchino Department of Ophthalmology, School of Medicine,
More informationROP and Imaging. Deborah M Costakos MD, MS August 12, 2016
ROP and Imaging Deborah M Costakos MD, MS August 12, 2016 Acknowledgements Adam Dubis, Ph.D. Joseph Carroll, Ph.D. Ryan Vogel, MD Clinton Warren, MD C Devika Subramaniam, M.D. Fouad Zakla, M.D. Alana Trotter,
More informationRecurrence of ROP after Anti-VEGF Therapy: How Many, Which Ones, When, What, Where
Recurrence of ROP after Anti-VEGF Therapy: How Many, Which Ones, When, What, Where Helen Mintz-Hittner, M.D. Department of Ophthalmology and Visual Science University of Texas-Health Science Center-Houston
More informationOCT Assessment of the Vitreoretinal Relationship in CSME
December 2007 Sonia Rani John et al. - IFIS 375 ORIGINAL ARTICLE OCT Assessment of the Vitreoretinal Relationship in CSME Dr. Manoj S. DNB FRCS, Dr. Unnikrishnan Nair MS DO FRCS, Dr. Gargi Sathish MS Introduction
More informationSUMMARY. Heather Casparis, MD,* and Neil M. Bressler, MD MARINA AND ANCHOR
The following are summaries of selected presentations and posters from the American Society of Retina Specialists and European VitreoRetinal Society Annual Meeting held September 9 13, 2006, in Cannes,
More informationR etinopathy of prematurity (ROP), a condition confined
F240 ORIGINAL ARTICLE UK population based study of severe retinopathy of prematurity: screening, treatment, and outcome L Haines, A R Fielder, H Baker, A R Wilkinson... See end of article for authors affiliations...
More informationA LONGITUDINAL DESCRIPTIVE STUDY ON RETINOPATHY OF PREMATURITY IN A TERTIARY CARE CENTRE IN SOUTH INDIA
A LONGITUDINAL DESCRIPTIVE STUDY ON RETINOPATHY OF PREMATURITY IN A TERTIARY CARE CENTRE IN SOUTH INDIA Mary Thomas 1, Sri Gautham Bodduluri 2, Krishnaja Mandava 3, M. Muthayya 4, Binu Ninan 5 1Associate
More informationDr. Derek P. Brazil Centre for Vision and Vascular Science Queen s University Belfast
Vascular Stem Cells as a novel potential treatment for Retinopathy of Prematurity Dr. Derek P. Brazil Centre for Vision and Vascular Science Queen s University Belfast Centre for Vision and Vascular Science
More informationClinical Study Incidence of Retinopathy of Prematurity in Extremely Premature Infants
ISRN Pediatrics, Article ID 134347, 4 pages http://dx.doi.org/10.1155/2014/134347 Clinical Study Incidence of Retinopathy of Prematurity in Extremely Premature Infants Alparslan Fahin, Muhammed Fahin,
More informationScreening for retinopathy of prematurity at Cipto Mangunkusumo Hospital, Jakarta, Indonesia a preliminary report
ACTA MEDICA LITUANICA. 2006. VOLUME 13 No. 3. P. 165 170 Lietuvos mokslų akademija, 2006 Screening for retinopathy of prematurity at Cipto Mangunkusumo Hospital, Jakarta, Indonesia... 165 Lietuvos mokslų
More informationRETINOPATHY OF PREMATURITY: INVOLUTION, FACTORS PREDISPOSING TO RETINAL DETACHMENT, AND EXPECTED UTILITY OF PREEMPTIVE SURGICAL REINTERVENTION
RETINOPATHY OF PREMATURITY: INVOLUTION, FACTORS PREDISPOSING TO RETINAL DETACHMENT, AND EXPECTED UTILITY OF PREEMPTIVE SURGICAL REINTERVENTION BY David K. Coats MD ABSTRACT Purpose: To characterize involution
More informationPCMCH ROP Screening Guidelines
PCMCH ROP Screening Guidelines An expert panel convened by PCMCH (the ROP Work Group) recommends the Canadian Paediatric Society s 2010 guidelines be adopted as Ontario s screening guidelines for ROP.
More informationRetinal photocoagulation for proliferative sickle cell retinopathy: A prospective clinical trial with new sea fan classification
European Journal of Ophthalmology / Vol. 18 no. 2, 2008 / pp. 248-254 Retinal photocoagulation for proliferative sickle cell retinopathy: A prospective clinical trial with new sea fan classification D.
More informationIn the treatment of neovascular and. Original Research
Original Research Hellenic J Cardiol 2013; 54: 435-440 Influence of Intravitreal Injection of Bevacizumab on Systemic Blood Pressure Changes in Patients with Exudative Form of Age-Related Macular Degeneration
More informationAnti-vascular endothelial growth factor treatment for retinopathy of prematurity
Review Article Page 1 of 7 Anti-vascular endothelial growth factor treatment for retinopathy of prematurity Qiujing Huang, Peiquan Zhao Department of Ophthalmology, Xin Hua Hospital Affiliated to Shanghai
More informationNote: This is an outcome measure and will be calculated solely using registry data.
Measure #384: Adult Primary Rhegmatogenous Retinal Detachment Surgery: No Return to the Operating Room Within 90 Days of Surgery National Quality Strategy Domain: Effective Clinical Care 2017 OPTIONS FOR
More informationClinical Outcomes After Intravitreal Bevacizumab Injection for Diabetic Macular Edema
Original Article Clinical Outcomes After Intravitreal Bevacizumab Injection for Diabetic Macular Edema Karen Joyce G. Castro, MD, Marie Joan V. Loy, MD International Eye Institute St. Luke s Medical Center
More informationIN NICU OCT UTILIZES A CONCEPT KNOWN AS INTERFEROMETRY APPLICATIONS FOR OCT THE PRIMARY USE IN THE EYE - RETINA
2016 25 YEARS OF OPTICAL COHERENCE TOMOGRAPHY OPTICAL COHERENCE TOMOGRAPHY IN NICU Marcin Stopa, MD, PhD, FEBO Department of Ophthalmology, Chair of Ophthalmology and Optometry. Poznan University of Medical
More informationVitreous changes after intravitreal bevacizumab monotherapy for retinopathy of prematurity: a case series
https://doi.org/10.1186/s40942-018-0113-3 International Journal of Retina and Vitreous ORIGINAL ARTICLE Open Access Vitreous changes after intravitreal bevacizumab monotherapy for retinopathy of prematurity:
More informationEyeGene Inc. Contact Information Korea Health Industry Development Institute
EG-Mirotin: First-in-Class recombinant polypeptide novel subcutaneous drug containing RGD-motif targeted to suppress edema and vascular leakage for Nonproliferative Diabetic Retinopathy (NPDR) EyeGene
More informationEffects of an Intravitreal Bevacizumab Injection Combined With Panretinal Photocoagulation on High-Risk Proliferative Diabetic Retinopathy
Korean Journal of Ophthalmology 2009;23:266-272 ISSN : 1011-8942 DOI : 10.3341/kjo.2009.23.4.266 Effects of an Intravitreal Bevacizumab Injection Combined With Panretinal Photocoagulation on High-Risk
More informationStudy of clinical significance of optical coherence tomography in diagnosis & management of diabetic macular edema
Original Research Article Study of clinical significance of optical coherence tomography in diagnosis & management of diabetic macular edema Neha Kantilal Desai 1,*, Somesh Vedprakash Aggarwal 2, Sonali
More informationTop Pediatric Retinal Diseases you don t want to miss! Retinopathy of Prematurity (ROP) Aggressive, Posterior ROP (AP ROP)
Top 10 10 Pediatric Retinal Diseases you don t want to miss! Polly Quiram MD, PhD Vitreoretinal Surgery, PA Retinal Update Jan 26th, 2018 ROP Retinoblastoma Coats disease Persistent fetal vasculature Familial
More informationAcute Retinal Necrosis Secondary to Varicella Zoster Virus in an Immunosuppressed Post-Kidney Transplant Patient
CM&R Rapid Release. Published online ahead of print September 20, 2012 as Aperture Acute Retinal Necrosis Secondary to Varicella Zoster Virus in an Immunosuppressed Post-Kidney Transplant Patient Elizabeth
More informationScreening Examination of Premature Infants for Retinopathy of Prematurity
POLICY STATEMENT Organizational Principles to Guide and Define the Child Health Care System and/or Improve the Health of all Children Screening Examination of Premature Infants for Retinopathy of Prematurity
More informationVanderbilt Eye Institute Clinical Trials
April, 2010 Vanderbilt Eye Institute Clinical Trials Ophthalmology Actively Recruiting Studies For information on our clinical trials and other studies, please contact: Sandy Owings, COA, CCRP Clinic Director
More informationDiabetic Retinopathy WHAT IS DIABETIC RETINOPATHY? WHAT CAUSES DIABETIC RETINOPATHY? WHAT ARE THE STAGES OF DIABETIC RETINOPATHY?
Diabetic Retinopathy WHAT IS DIABETIC RETINOPATHY? Diabetic retinopathy affects 8 million Americans with diabetes. A leading cause of blindness in American adults, it is caused by damage to the small blood
More informationCOMPARISON OF INTRAVITREAL TRIAMCINOLONE INJECTION VS LASER PHOTOCOAGULATION IN ANGIOGRAPHIC MACULAR EDEMA IN DIABETIC RETINOPATHY
Original Article COMPARISON OF INTRAVITREAL TRIAMCINOLONE INJECTION VS LASER PHOTOCOAGULATION IN ANGIOGRAPHIC MACULAR EDEMA IN DIABETIC RETINOPATHY Aggarwal Somesh V 1, Shah Sonali N 2, Bharwada Rekha
More informationClinical Trials in Diabetic Retinopathy. Harry W. Flynn Jr., M.D. Nidhi Relhan Batra, M.D.
1 Clinical Trials in Diabetic Retinopathy 2018 Harry W. Flynn Jr., M.D. Nidhi Relhan Batra, M.D. Bascom Palmer Eye Institute 900 N.W. 17th Street Miami, FL 33136 Phone: (305) 326-6118 Fax: (305) 326-6417
More information